Guardant Health to Present Groundbreaking Precision Oncology Data at ESMO 2024
2 Sources
2 Sources
[1]
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types By Investing.com
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360 ® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). Our latest data featured at ESMO further highlight the value of Guardant's technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types, said Craig Eagle, M.D., chief medical officer at Guardant Health (NASDAQ:GH). We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care. Complete list of Guardant Health and collaborator presentations at ESMO 2024 The full abstracts for Guardant Health and a list of all abstracts being presented at the ESMO Congress can be found on the ESMO website. Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operation and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
[2]
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). "Our latest data featured at ESMO further highlight the value of Guardant's technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types," said Craig Eagle, M.D., chief medical officer at Guardant Health. "We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care." Complete list of Guardant Health and collaborator presentations at ESMO 2024 The full abstracts for Guardant Health and a list of all abstracts being presented at the ESMO Congress can be found on the ESMO website. Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Share
Share
Copy Link
Guardant Health announces plans to share new data at ESMO 2024, showcasing the performance of its precision oncology technology across multiple advanced tumor types. The presentations will highlight the company's liquid biopsy tests and their potential impact on cancer treatment decisions.
Guardant Health's ESMO 2024 Presentations
Guardant Health, a leading precision oncology company, is set to present significant new data at the European Society for Medical Oncology (ESMO) Congress 2024. The company will showcase the performance of its cutting-edge precision oncology technology across various advanced tumor types, demonstrating its commitment to improving cancer care through innovative diagnostic solutions
1
.Key Highlights of the Presentations
The presentations will focus on Guardant Health's liquid biopsy tests, including the Guardant360® CDx and Guardant360 TissueNext™ tests. These tests are designed to provide comprehensive genomic profiling for patients with advanced cancers, offering valuable insights to inform treatment decisions
2
.Guardant360 CDx Test Performance
One of the key presentations will highlight the strong performance of the Guardant360 CDx test in detecting clinically relevant genomic alterations across multiple advanced solid tumor types. This data underscores the test's potential to guide treatment decisions for a wide range of cancer patients
1
.Guardant360 TissueNext Test Insights
Another presentation will focus on the Guardant360 TissueNext test, showcasing its ability to provide comprehensive genomic profiling results from small tissue samples. This capability is particularly crucial for patients with limited available tissue for testing, offering an alternative solution for genomic profiling
2
.Impact on Treatment Decisions
The data to be presented at ESMO 2024 will demonstrate how Guardant Health's precision oncology tests can significantly impact treatment decisions for patients with advanced cancers. By providing comprehensive genomic information, these tests enable oncologists to make more informed choices about targeted therapies and clinical trial eligibility
1
2
.Related Stories
Advancing Precision Medicine in Oncology
Guardant Health's presence at ESMO 2024 reinforces its position as a leader in the field of precision oncology. The company's ongoing research and development efforts aim to expand the utility of liquid biopsy tests and improve patient outcomes through personalized treatment approaches
2
.Future Implications
The data presented at ESMO 2024 is expected to have far-reaching implications for the field of oncology. As precision medicine continues to evolve, Guardant Health's technologies are poised to play a crucial role in shaping the future of cancer diagnosis and treatment, potentially leading to improved patient outcomes and more efficient use of healthcare resources
1
2
.References
Summarized by
Navi
Related Stories
Weekly Highlights
1
Anthropic Secures $13B in Funding, Reaching $183B Valuation Amid AI Industry Boom
Business and Economy
2
Tesla Proposes $1 Trillion Pay Package for Elon Musk Tied to Ambitious AI and Robotics Goals
Business and Economy
3
Anthropic's $1.5B AI Copyright Settlement: A Landmark Deal Under Scrutiny
Policy and Regulation
Weekly Highlights
Explore today's top stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
